Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review
Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved..
Multiparametric magnetic resonance imaging (mpMRI) has high sensitivity but low specificity for prostate cancer (PCa) diagnosis. The aim of our systematic review was to investigate the proportion of PCa found at a repeat biopsy in patients with a negative initial prostate biopsy, despite initial positive mpMRI. Included patients had a Prostate Imaging Reporting and Data System (PI-RADS)/Likert 3-5 lesion on mpMRI prior to the initial mpMRI-targeted prostate biopsy, which was negative for PCa on histology. The main outcomes were the overall and clinically significant PCa (csPCa; International Society of Urological Pathology >1 or any provided definition) percentages at a repeat biopsy. Out of 1179 articles identified, nine studies were included (a total of 485 patients). For patients with PI-RADS 3 lesions, overall and csPCa detection percentages ranged from 0% to 80% and from 0% to 20%, respectively, while for patients with PI-RADS ≥4 lesions, the corresponding percentages were 15.4-86% and 7.7-57%. An overall cancer detection percentage of 87.5% was reported in patients with Likert 5 lesions. Limitation of our review is the small number of studies and the protocol revision that allowed studies with <50 patients. In patients with a positive MRI result and a negative initial MRI-targeted biopsy, we suggest MRI re-reading and follow-up with repeat mpMRI or the standard repeat biopsy in cases at the highest risk. PATIENT SUMMARY: Literature has shown that in men with an abnormal prostate magnetic resonance imaging (MRI) scan but a normal biopsy, a significant prostate cancer can be present. MRI scans should be double checked, followed by standard checkups or repeat prostate biopsy, especially in highly suspicious cases.
| Errataetall: |
CommentIn: Asian J Surg. 2023 Jun;46(6):2527. - PMID 36610909 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:82 |
|---|---|
| Enthalten in: |
European urology - 82(2022), 5 vom: 16. Nov., Seite 452-457 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Grivas, Nikolaos [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 18.10.2022 Date Revised 07.06.2023 published: Print-Electronic CommentIn: Asian J Surg. 2023 Jun;46(6):2527. - PMID 36610909 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.eururo.2022.07.025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34504441X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34504441X | ||
| 003 | DE-627 | ||
| 005 | 20231226024155.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eururo.2022.07.025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1150.xml |
| 035 | |a (DE-627)NLM34504441X | ||
| 035 | |a (NLM)35985901 | ||
| 035 | |a (PII)S0302-2838(22)02540-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Grivas, Nikolaos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2022 | ||
| 500 | |a Date Revised 07.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Asian J Surg. 2023 Jun;46(6):2527. - PMID 36610909 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Multiparametric magnetic resonance imaging (mpMRI) has high sensitivity but low specificity for prostate cancer (PCa) diagnosis. The aim of our systematic review was to investigate the proportion of PCa found at a repeat biopsy in patients with a negative initial prostate biopsy, despite initial positive mpMRI. Included patients had a Prostate Imaging Reporting and Data System (PI-RADS)/Likert 3-5 lesion on mpMRI prior to the initial mpMRI-targeted prostate biopsy, which was negative for PCa on histology. The main outcomes were the overall and clinically significant PCa (csPCa; International Society of Urological Pathology >1 or any provided definition) percentages at a repeat biopsy. Out of 1179 articles identified, nine studies were included (a total of 485 patients). For patients with PI-RADS 3 lesions, overall and csPCa detection percentages ranged from 0% to 80% and from 0% to 20%, respectively, while for patients with PI-RADS ≥4 lesions, the corresponding percentages were 15.4-86% and 7.7-57%. An overall cancer detection percentage of 87.5% was reported in patients with Likert 5 lesions. Limitation of our review is the small number of studies and the protocol revision that allowed studies with <50 patients. In patients with a positive MRI result and a negative initial MRI-targeted biopsy, we suggest MRI re-reading and follow-up with repeat mpMRI or the standard repeat biopsy in cases at the highest risk. PATIENT SUMMARY: Literature has shown that in men with an abnormal prostate magnetic resonance imaging (MRI) scan but a normal biopsy, a significant prostate cancer can be present. MRI scans should be double checked, followed by standard checkups or repeat prostate biopsy, especially in highly suspicious cases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Multiparametric magnetic resonance imaging | |
| 650 | 4 | |a Negative prostate biopsy | |
| 650 | 4 | |a Prostate cancer | |
| 700 | 1 | |a Lardas, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Espinós, Estefania Linares |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Thomas B |e verfasserin |4 aut | |
| 700 | 1 | |a Rouviere, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Mottet, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a van den Bergh, Roderick C N |e verfasserin |4 aut | |
| 700 | 0 | |a Members of the EAU-EANM-ESTRO-ESUR-ISUP-SIOG Prostate Cancer Guidelines Panel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European urology |d 1977 |g 82(2022), 5 vom: 16. Nov., Seite 452-457 |w (DE-627)NLM000137588 |x 1873-7560 |7 nnns |
| 773 | 1 | 8 | |g volume:82 |g year:2022 |g number:5 |g day:16 |g month:11 |g pages:452-457 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eururo.2022.07.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 82 |j 2022 |e 5 |b 16 |c 11 |h 452-457 | ||